Profectus BioSciences, Inc.

FOR IMMEDIATE RELEASE

Profectus BioSciences, Inc. is Awarded a Phase II SBIR Totaling $2 Million to Develop Prophylactic Vaccines Against HIV Based on its Transition State Vaccine and Recombinant VSV Technology

BALTIMORE, Md., October 23, 2015 – Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a Phase II Small Business Innovative Research grant from the Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH. This award supports the development of a novel prophylactic HIV-1 vaccine based on the company's Full Length Single Chain (FLSC) delivered by the company's recombinant Vesicular stomatitis virus (rVSV) vector platform. The Full Length Single Chain is a complex of gp120 and its cognate receptor CD4 to form a transition state structure that directs the immune responses towards conserved "tender parts" of HIV. These FLSC complexes raise cross-reactive antibodies and protective immune responses against SIV in macaques, an animal model for HIV. These results prompted the evaluation of FLSC subunit in an imminent phase I clinical trial. The company believes it can improve the potency, durability and efficacy of the resulting immune response by incorporating the FLSC into rVSV. If successful, the company believes it can move this new vaccine into preclinical development given the proven track record of safety and immunogenicity of rVSV in humans (HVTN-090).

About Profectus BioSciences

Profectus BioSciences is a clinical-stage vaccine company developing innovative vaccines for the prevention and treatment of infectious diseases and the treatment of cancer. Profectus vaccines are based on the company's proprietary VesiculoVax™ and DNA vaccine delivery platforms. Used alone, the first-in-class VesiculoVax™-vectored vaccines lead to rapid expansion of B cells to provide protection against emerging infectious diseases of public health and biodefense importance such as Ebola, Marburg, Chikungunya, and the Equine Encephalitis viruses. When used as a boost after priming the immune system with best-in-class pDNA vaccines, VesiculoVax™-vectored vaccines lead to the expansion of primed T cells into effector cells that are uniquely suited to killing virally infected cells and cancers. Current programs using the Prime/Boost System of Vaccines (PBS Vax™) strategy include hepatitis B virus (HBV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2), and human immunodeficiency virus (HIV). Partners and collaborators include the Galveston National Laboratory at UTMB, Yale University, the Institute of Human Virology, the Center for HIV/AIDS Vaccine Immunology, the National Cancer Institute, the NIH Division of AIDS, the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative, the HIV Vaccines Trials Network, and the AIDS Clinical Trials Group. Profectus has been funded by Cross

Atlantic Capital Partners ("XACP") of Radnor, Pennsylvania. XACP's primary investor is the Pennsylvania Public School Employees' Retirement System (PSERS). For more information, please visit www.profectusbiosciences.com.

###

Contact:

Jeffrey N. Meshulam
President
Profectus BioSciences, Inc.
443-743-1100
Meshulam@profectusbiosciences.com